Ralaniten
Clinical data
Other namesEPI-002
Drug classNonsteroidal antiandrogen
Identifiers
  • (2R)-3-[4-[2-[4-[(2S)-3-Chloro-2-hydroxypropoxy]phenyl]propan-2-yl]phenoxy]propane-1,2-diol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC21H27ClO5
Molar mass394.89 g·mol−1
3D model (JSmol)
  • CC(C)(C1=CC=C(C=C1)OC[C@@H](CO)O)C2=CC=C(C=C2)OC[C@@H](CCl)O
  • InChI=1S/C21H27ClO5/c1-21(2,15-3-7-19(8-4-15)26-13-17(24)11-22)16-5-9-20(10-6-16)27-14-18(25)12-23/h3-10,17-18,23-25H,11-14H2,1-2H3/t17-,18-/m1/s1
  • Key:HDTYUHNZRYZEEB-QZTJIDSGSA-N

Ralaniten (developmental code name EPI-002) is an N-terminal domain antiandrogen which was never marketed.[1] It is a derivative of bisphenol A[2] and one of the four stereoisomers of EPI-001.[1] A prodrug of ralaniten, ralaniten acetate (EPI-506), was under development for the treatment of prostate cancer.[3]

See also

References

  1. 1 2 Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, et al. (July 2013). "An androgen receptor N-terminal domain antagonist for treating prostate cancer". The Journal of Clinical Investigation. 123 (7): 2948–2960. doi:10.1172/JCI66398. PMC 3696543. PMID 23722902.
  2. ↑ Monaghan AE, McEwan IJ (2016). "A sting in the tail: the N-terminal domain of the androgen receptor as a drug target". Asian Journal of Andrology. 18 (5): 687–694. doi:10.4103/1008-682X.181081. PMC 5000789. PMID 27212126.
  3. ↑ Maughan BL, Antonarakis ES (December 2015). "Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer". Current Treatment Options in Oncology. 16 (12): 57. doi:10.1007/s11864-015-0375-z. PMID 26537882. S2CID 30398927.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.